Angle founder and CEO steps down after shareholder backlash
12th Sep 2025 07:26
(Sharecast News) - Liquid biopsy company Angle has announced the resignations of its chief executive and finance director "following feedback and discussions with a significant shareholder".
Read moreShares in Angle tumble on gloomy outlook
9th Sep 2025 07:18
(Sharecast News) - Shares in Angle plunged on Tuesday, after the AIM-listed biotech warned full-year revenues risked being "significantly" constrained.
Read moreAngle reviewing board structure as two directors exit
6th Jun 2025 08:12
(Sharecast News) - Shares in Angle dropped sharply on Friday after the cancer treatment tech firm announcement the abrupt resignation of two boardmembers.
Read moreAngle slumps on cautious outlook
28th May 2025 09:34
(Sharecast News) - Shares in Angle tanked on Wednesday after the cancer treatment tech group delivered a cautious outlook, pointing to only "modest" growth compared with the 31% surge in revenues seen in 2024.
Read moreAngle completes assay development projects
21st Mar 2025 11:05
(Sharecast News) - Angle announced on Friday the successful completion of assay development projects for AstraZeneca and Eisai, further expanding its portfolio of liquid biopsy solutions and strengthening its position as a partner to the pharmaceutical industry in oncology drug development.
Read moreAngle's Parsortix system used in 'breakthrough' breast cancer research
24th Jan 2025 10:51
(Sharecast News) - Liquid biopsy specialist Angle announced on Friday that its Parsortix system played a pivotal role in groundbreaking breast cancer research published in Nature Medicine by a team led by professor Nicola Aceto at ETH Zurich.
Read moreBerenberg slashes target price on Angle
23rd Jan 2025 11:21
(Sharecast News) - Analysts at Berenberg slashed their target price on liquid biopsy specialist Angle from 70.0p to 40.0p on Thursday but said the group was "repositioned for growth" in FY25.
Read moreAngle signs new agreement US biotech Recursion
19th Sep 2024 12:40
(Sharecast News) - Angle's share price received a boost on Thursday after the liquid biopsy company announced a new agreement with Utah-based biotech firm Recursion Pharmaceuticals.
Read moreAngle unveils plans to raise more than £10m
5th Jun 2024 10:08
(Sharecast News) - Liquid biopsy specialist Angle is to raise more than £10m to support future growth, the UK company announced on Wednesday.
Read moreAngle reports promising results from Parsortix study
16th May 2024 11:46
(Sharecast News) - Angle, the AIM-listed liquid biopsy company which specialises in circulating tumour cell (CTC) solutions, has announced the results of a clinical study which show that its Parsortix system could be used to predict progression-free survival in patients with ovarian cancer.
Read moreAngle strikes supplier deal with AstraZeneca
3rd May 2024 07:58
(Sharecast News) - Liquid biopsy technology firm Angle has struck a supplier deal with pharmaceutical giant AstraZeneca to develop an androgen receptor detection assay to enhance prostate cancer studies.
Read moreAngle granted European patent for CellKeep, US patent imminent
22nd Apr 2024 06:59
(Sharecast News) - Liquid biopsy specialist Angle announced on Monday that it has received a European patent for its 'CellKeep' slide, as it anticipated the imminent grant of an equivalent US patent application.
Read moreAngle receives 'breakthrough results' from DNA molecular analysis
4th Jan 2024 07:58
(Sharecast News) - Liquid biopsy company Angle received "breakthrough results" from DNA molecular analysis of cancer patient blood samples on Thursday, sending its shares skywards as a result.
Read moreAngle locks in $250,000 contract with Eisai
2nd Jan 2024 09:04
(Sharecast News) - Liquid biopsy company Angle has locked in a $250,000 contract with global pharmaceutical company Eisai to deliver circulating tumour cell analysis in a pilot study.
Read moreAngle losses widen in 'breakthrough year'
21st Apr 2023 11:06
(Sharecast News) - Liquid biopsy specialist Angle described a "breakthrough year" in its 2022 results on Friday, with both FDA clearance and positive results from the ovarian cancer study being achieved.
Read more